Comparison 3. Treatment of upper gastrointestinal bleeding: subgroup analysis higher versus lower dose inhibitor of gastric acid.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All cause mortality to near term age or discharge	2	131	Risk Ratio (M‐H, Fixed, 95% CI)	0.63 [0.26, 1.51]
1.1 Higher dose	1	83	Risk Ratio (M‐H, Fixed, 95% CI)	0.59 [0.15, 2.29]
1.2 Lower dose	1	48	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.22, 2.07]
2 Duration of upper gastrointestinal bleeding in infants with upper gastrointestinal bleeding (days)	2	104	Mean Difference (IV, Fixed, 95% CI)	‐1.06 [‐1.28, ‐0.84]
2.1 Higher dose	1	66	Mean Difference (IV, Fixed, 95% CI)	‐1.06 [‐1.28, ‐0.84]
2.2 Lower dose	1	38	Mean Difference (IV, Fixed, 95% CI)	‐9.5 [‐19.55, 0.55]
3 Continued upper gastrointestinal bleeding in infants with upper gastrointestinal bleeding at latest time reported	6	451	Risk Ratio (M‐H, Fixed, 95% CI)	0.36 [0.26, 0.49]
3.1 Higher dose	3	207	Risk Ratio (M‐H, Fixed, 95% CI)	0.46 [0.33, 0.64]
3.2 Lower dose	3	244	Risk Ratio (M‐H, Fixed, 95% CI)	0.19 [0.09, 0.42]